Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo OKs Insurance Coverage for Chugai’s Companion Diagnostic to Rozlytrek
The Central Social Insurance Medical Council, better known as Chuikyo, approved on October 18 insurance coverage for Chugai Pharmaceutical’s comprehensive genomic profiling test FoundationOne CDx Cancer Genomic Profile as a companion diagnostic to the ROS1/TRK inhibitor Rozlytrek (entrectinib) for the…
To read the full story
Related Article
- Chugai’s Companion Diagnostic OK’ed for Rozlytrek’s ROS1 Use
December 27, 2019
- Chuikyo Approves Coverage for Chugai’s FoundationOne as Companion Diagnostic for Lynparza
December 16, 2019
- Japan OKs Companion Diagnostic for Rozlytrek: Chugai
June 28, 2019
- Chugai’s Gene Mutation Analysis Program Now Available in Japan
June 4, 2019
REGULATORY
- DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
- MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…